| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2006-10-17 10:02:55 UTC |
|---|
| Update Date | 2020-02-26 21:25:41 UTC |
|---|
| HMDB ID | HMDB0005033 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Valdecoxib |
|---|
| Description | Valdecoxib, also known as bextra or kudeq, belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring. A former Pfizer district sales manager was indicted and sentenced to home confinement for destroying documents regarding the illegal promotion of Bextra. Valdecoxib is a drug which is used for the treatment of osteoarthritis and dysmenorrhoea. Valdecoxib is an extremely weak basic (essentially neutral) compound (based on its pKa). In humans, valdecoxib is involved in valdecoxib action pathway. Valdecoxib has analytical methods for bioequivalence studies, metabolite determination, estimation of formulation, and an HPTLC method for simultaneous estimation in tablet dosage form. Pfizer first acknowledged cardiovascular risks associated with Bextra in October 2004. and was available by prescription in tablet form until 2005 when the FDA requested that Pfizer withdraw Bextra from the American market. In the United States, the Food and Drug Administration (FDA) approved valdecoxib for the treatment of osteoarthritis, adult rheumatoid arthritis, and primary dysmenorrhea. Six whistle-blowers were awarded more than $102 million for their role in the investigation. |
|---|
| Structure | CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20) |
|---|
| Synonyms | | Value | Source |
|---|
| 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide | ChEBI | | Bextra | ChEBI | | p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide | ChEBI | | Valdecoxibum | ChEBI | | 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulphonamide | Generator | | p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulphonamide | Generator | | COX | HMDB | | Kudeq | HMDB | | Valdyn | HMDB | | Valecoxib | HMDB | | Pfizer brand OF valdecoxib | HMDB |
|
|---|
| Chemical Formula | C16H14N2O3S |
|---|
| Average Molecular Weight | 314.359 |
|---|
| Monoisotopic Molecular Weight | 314.072513014 |
|---|
| IUPAC Name | 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzene-1-sulfonamide |
|---|
| Traditional Name | valdecoxib |
|---|
| CAS Registry Number | 181695-72-7 |
|---|
| SMILES | CC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=O |
|---|
| InChI Identifier | InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20) |
|---|
| InChI Key | LNPDTQAFDNKSHK-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Benzenesulfonamides |
|---|
| Direct Parent | Benzenesulfonamides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzenesulfonamide
- Benzenesulfonyl group
- Organosulfonic acid amide
- Azole
- Isoxazole
- Organic sulfonic acid or derivatives
- Organosulfonic acid or derivatives
- Heteroaromatic compound
- Aminosulfonyl compound
- Sulfonyl
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxygen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 160 - 162 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.32 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.7291 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.03 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 27.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1999.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 358.7 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 182.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 207.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 284.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 452.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 551.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 138.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1232.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 450.1 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1202.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 345.4 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 415.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 318.8 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 305.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 72.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Valdecoxib,1TMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N[Si](C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 2953.0 | Semi standard non polar | 33892256 | | Valdecoxib,1TMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N[Si](C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 2784.6 | Standard non polar | 33892256 | | Valdecoxib,1TMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N[Si](C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 3954.0 | Standard polar | 33892256 | | Valdecoxib,2TMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 2875.2 | Semi standard non polar | 33892256 | | Valdecoxib,2TMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 2961.2 | Standard non polar | 33892256 | | Valdecoxib,2TMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N([Si](C)(C)C)[Si](C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 3830.3 | Standard polar | 33892256 | | Valdecoxib,1TBDMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 3165.0 | Semi standard non polar | 33892256 | | Valdecoxib,1TBDMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 3024.5 | Standard non polar | 33892256 | | Valdecoxib,1TBDMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N[Si](C)(C)C(C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 3903.9 | Standard polar | 33892256 | | Valdecoxib,2TBDMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 3362.3 | Semi standard non polar | 33892256 | | Valdecoxib,2TBDMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 3406.3 | Standard non polar | 33892256 | | Valdecoxib,2TBDMS,isomer #1 | CC1=C(C2=CC=C(S(=O)(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C2)C(C2=CC=CC=C2)=NO1 | 3789.7 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Valdecoxib GC-MS (Non-derivatized) - 70eV, Positive | splash10-01qa-0290000000-adad99d8d7c023e6f63b | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valdecoxib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Valdecoxib LC-ESI-qTof , Positive-QTOF | splash10-0089-2930000000-dac70ddadd2ffd150b22 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valdecoxib , positive-QTOF | splash10-014i-0439000000-984ffa23e74fb8949b56 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valdecoxib , positive-QTOF | splash10-014i-0439000000-8928b5e8f850f43f1430 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valdecoxib , positive-QTOF | splash10-0089-2930000000-dac70ddadd2ffd150b22 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valdecoxib 35V, Positive-QTOF | splash10-001i-0941000000-0931692fec04d3e19f52 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valdecoxib 35V, Negative-QTOF | splash10-03di-0689000000-764e252bae3ae694704a | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 10V, Positive-QTOF | splash10-014i-0019000000-596b73746ee066f35968 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 20V, Positive-QTOF | splash10-014i-0049000000-818c4a70e42df2b88f8a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 40V, Positive-QTOF | splash10-0pbi-0390000000-13714d8251c6a02a4053 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 10V, Negative-QTOF | splash10-03di-0009000000-a2f711c3743b82164d6d | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 20V, Negative-QTOF | splash10-03di-0029000000-2ac37e780c7fe646fc3e | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 40V, Negative-QTOF | splash10-004i-9460000000-fb4b9f778483757805ea | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 10V, Negative-QTOF | splash10-03di-0009000000-fa0317e9dc89d23da23a | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 20V, Negative-QTOF | splash10-03di-0009000000-fa0317e9dc89d23da23a | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 40V, Negative-QTOF | splash10-004i-9611000000-28d2f85d0f3c715b52fa | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 10V, Positive-QTOF | splash10-014i-0009000000-bba9fedad3067bb6377e | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 20V, Positive-QTOF | splash10-014i-0039000000-4c17bb46a939879efeea | 2021-09-24 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valdecoxib 40V, Positive-QTOF | splash10-0a6r-2960000000-ea456b0a645f35565a29 | 2021-09-24 | Wishart Lab | View Spectrum |
|
|---|
| Synthesis Reference | Rogers, Roland S.; Talley, John J.; Brown, David L.; Nagarajan, Srinivasan; Carter, Jeffery S.; Weier, Richard M.; Stealey, Michael A.; Collins, Paul W.; Seibert, Karen; et al. Substituted isoxazoles for the treatment of inflammation. PCT Int. Appl. (1996), 171 pp. CODEN: PIXXD2 WO 9625405 A1 19960822 CAN 125:247800 AN 1996:601794 |
|---|